Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Eur J Clin Pharmacol ; 80(8): 1229-1240, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-38695888

RESUMO

OBJECTIVE: Several population pharmacokinetic models of tacrolimus in liver transplant patients were built, and their predictability was evaluated in their settings. However, the extrapolation in the prediction was unclear. This study aimed to evaluate the predictive performance of published tacrolimus models in adult liver transplant recipients using data from the Thai population as an external dataset. METHODS: The selected published models were systematically searched and evaluated for their quality. The external dataset of patients who underwent the first liver transplant and received immediate-release tacrolimus was used to assess the predictive performance of each selected model. Trough concentrations between 3 and 6 months were retrospectively collected to evaluate the predictability of each model using prediction-based diagnostics, simulation-based diagnostics, and Bayesian forecasting. RESULTS: Sixty-seven patients with 360 trough concentrations and eight selected published models were included in this study. None of the models met the predictive precision criteria in prediction-based diagnostics. Meanwhile, four published population pharmacokinetic models showed a normal distribution in NPDE testing. Regarding Bayesian forecasting, all models improved their forecasts with at least one prior information data point. CONCLUSION: Bayesian forecasting is more accurate and precise than other testing methods for predicting drug concentrations. However, none of the evaluated models provides satisfactory predictive performance for generalization to Thai liver transplant patients. This underscores the need for future research to develop population PK models tailored to the Thai population. Such efforts should consider the inclusion of nonlinear pharmacokinetics and region-specific factors, including genetic variability, to improve model accuracy and applicability.


Assuntos
Teorema de Bayes , Imunossupressores , Transplante de Fígado , Modelos Biológicos , Tacrolimo , Humanos , Tacrolimo/farmacocinética , Tacrolimo/sangue , Imunossupressores/farmacocinética , Imunossupressores/sangue , Imunossupressores/uso terapêutico , Masculino , Feminino , Tailândia , Pessoa de Meia-Idade , Adulto , Estudos Retrospectivos , Idoso , População do Sudeste Asiático
3.
Clin Transl Gastroenterol ; 15(5): e00697, 2024 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-38488171

RESUMO

INTRODUCTION: Data on the relationship between bacterial translocation, hepatic encephalopathy (HE), and mortality are scarce. This study aimed to assess the association between bacterial DNA (bactDNA) translocation, inflammatory response, ammonia levels, and severity of HE in patients with cirrhosis, as well as the role of bactDNA translocation in predicting mortality. METHODS: Cirrhotic patients without bacterial infection were prospectively enrolled between June 2022 and January 2023. Grading of HE was classified by the West Haven Criteria and Psychometric Hepatic Encephalopathy Score ≤ -5. RESULTS: Overall, 294 cirrhotic patients were enrolled, with 92 (31.3%) and 58 (19.7%) having covert and overt HE, respectively. BactDNA translocation was detected in 36.1% of patients (n = 106). Patients with overt HE had more bactDNA translocation and higher serum lipopolysaccharide-binding protein (LBP), tumor necrosis factor-α, interleukin-6 (IL-6), and ammonia levels than those without HE. Patients with detectable bactDNA had higher white cell counts and serum LBP and IL-6 levels than those without. By contrast, bactDNA, serum LBP, and soluble CD14 levels were comparable between patients with covert HE and those without HE. The multivariate Cox regression analysis revealed that bactDNA translocation (hazard ratio [HR] = 2.49, 95% confidence interval [CI]: 1.22-5.11), Model for End-Stage Liver Disease score (HR = 1.12, 95% CI: 1.09-1.16), age (HR = 1.05, 95% CI: 1.000-1.002), and baseline IL-6 (HR = 1.001, 95% CI: 1.000-1.002) were independent factors associated with 6-month mortality. DISCUSSION: Apart from hyperammonemia, bactDNA translocation is a possible factor associated with overt HE in cirrhotic patients. BactDNA translocation and IL-6 are independent factors associated with 6-month mortality.


Assuntos
Translocação Bacteriana , DNA Bacteriano , Encefalopatia Hepática , Cirrose Hepática , Humanos , Encefalopatia Hepática/sangue , Encefalopatia Hepática/mortalidade , Encefalopatia Hepática/microbiologia , Masculino , Cirrose Hepática/sangue , Cirrose Hepática/mortalidade , Cirrose Hepática/microbiologia , Cirrose Hepática/complicações , Feminino , Pessoa de Meia-Idade , DNA Bacteriano/sangue , DNA Bacteriano/análise , DNA Bacteriano/isolamento & purificação , Estudos Prospectivos , Idoso , Amônia/sangue , Índice de Gravidade de Doença , Proteínas de Fase Aguda/análise , Proteínas de Transporte/sangue , Proteínas de Transporte/genética , Interleucina-6/sangue , Glicoproteínas de Membrana/sangue
4.
Clin Mol Hepatol ; 30(2): 191-205, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38190830

RESUMO

BACKGROUND/AIMS: Four-week treatment of linvencorvir (RO7049389) was generally safe and well tolerated, and showed anti-viral activity in chronic hepatitis B (CHB) patients. This study evaluated the efficacy, safety, and pharmacokinetics of 48-week treatment with linvencorvir plus standard of care (SoC) in CHB patients. METHODS: This was a multicentre, non-randomized, non-controlled, open-label phase 2 study enrolling three cohorts: nucleos(t)ide analogue (NUC)-suppressed patients received linvencorvir plus NUC (Cohort A, n=32); treatment-naïve patients received linvencorvir plus NUC without (Cohort B, n=10) or with (Cohort C, n=30) pegylated interferon-α (Peg-IFN-α). Treatment duration was 48 weeks, followed by NUC alone for 24 weeks. RESULTS: 68 patients completed the study. No patient achieved functional cure (sustained HBsAg loss and unquantifiable HBV DNA). By Week 48, 89% of treatment-naïve patients (10/10 Cohort B; 24/28 Cohort C) reached unquantifiable HBV DNA. Unquantifiable HBV RNA was achieved in 92% of patients with quantifiable baseline HBV RNA (14/15 Cohort A, 8/8 Cohort B, 22/25 Cohort C) at Week 48 along with partially sustained HBV RNA responses in treatment-naïve patients during follow-up period. Pronounced reductions in HBeAg and HBcrAg were observed in treatment-naïve patients, while HBsAg decline was only observed in Cohort C. Most adverse events were grade 1-2, and no linvencorvir-related serious adverse events were reported. CONCLUSION: 48-week linvencorvir plus SoC was generally safe and well tolerated, and resulted in potent HBV DNA and RNA suppression. However, 48-week linvencorvir plus NUC with or without Peg-IFN did not result in the achievement of functional cure in any patient.


Assuntos
Antivirais , Hepatite B Crônica , Imidazóis , Pirazinas , Humanos , Antivirais/efeitos adversos , Capsídeo , DNA Viral , Antígenos E da Hepatite B , Antígenos de Superfície da Hepatite B , Vírus da Hepatite B/genética , Hepatite B Crônica/tratamento farmacológico , Polietilenoglicóis , RNA , Padrão de Cuidado , Resultado do Tratamento
5.
Sci Rep ; 13(1): 22633, 2023 12 19.
Artigo em Inglês | MEDLINE | ID: mdl-38114689

RESUMO

Knowledge about the epidemiology of hepatitis D virus (HDV) is essential for effective screening and management. Our study aimed to update the prevalence of HDV infection among patients with hepatitis B virus (HBV) infection at hepatology clinics in Thailand. We enrolled HBV-infected patients from hepatology clinics at King Chulalongkorn Memorial Hospital, Bangkok, Thailand, between June 2022 and November 2023. Demographic, biochemical characteristics, and liver-related complications (LRC), including cirrhosis and hepatocellular carcinoma, were reviewed. The competitive enzyme and chemiluminescence immunoassays were used to detect anti-HDV antibodies. Real-time polymerase chain reaction (RT-PCR) was used to test for HDV RNA in anti-HDV-positive patients. The HDV genotype was identified in detectable HDV RNA samples. Of the 702 enrolled patients, four (0.6%) had positive and equivocal for both anti-HDV tests. Two (50.0%) of the four patients tested positive for HDV RNA and genotype 1 was identified; one had multiple risk factors. Anti-HDV seroprevalence was not significantly different between patients with and without LRC. In conclusion, HDV co-infection is less common in Thailand than globally. Additionally, our study identified genotype 1, the predominant HDV genotype worldwide, and observed co-infection even without LRC.


Assuntos
Coinfecção , Hepatite B Crônica , Hepatite B , Hepatite D , Neoplasias Hepáticas , Humanos , Vírus Delta da Hepatite/genética , Hepatite B Crônica/complicações , Hepatite B Crônica/epidemiologia , Prevalência , Centros de Atenção Terciária , Coinfecção/epidemiologia , Coinfecção/complicações , Tailândia/epidemiologia , RNA Viral/genética , RNA Viral/análise , Genótipo , Hepatite D/complicações , Hepatite D/epidemiologia , Hepatite B/complicações , Hepatite B/epidemiologia , Vírus da Hepatite B/genética , Antígenos de Superfície da Hepatite B/genética , Neoplasias Hepáticas/complicações
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA